Photo by RDNE Stock project on Pexels. Hands exchanging paperwork.
A company says it can sell hundreds of millions of dollars of shares. How much money has arrived? The answer may be none under that particular arrangement. A funding limit describes what could be sold; proceeds describe a transaction that happened.
That distinction matters when reading small-company disclosures, where a large financing number can dominate the story. It also travels beyond penny stocks. The three Nasdaq-listed companies below illustrate different disclosure states, rather than a claim that all three currently meet a legal definition of a penny stock.
Published filings checked on 20 October 2026 show unused capacity at Plug Power, an expired agreement at Novavax and a completed offering at FuelCell Energy. The dates matter. These are reported historical positions, not live balances or announcements of new transactions today.
Fact: capacity can remain unused
Plug Power (NASDAQ: PLUG) describes an at-the-market, or ATM, equity programme in its June 2026 quarterly filing. Such a programme provides a route for selling shares over time through agreed arrangements. The programme’s limit is different from a deposit in the bank.
Plug reported $944.1 million of aggregate gross sales capacity remaining at 30 June. It also reported no shares sold under that ATM programme during the six months then ended. Those statements can both be true: available capacity and actual use measure different things.
In a later 15 October update, Plug said it had received no ATM proceeds or other equity or debt capital-raising proceeds during the third quarter. That statement accompanied preliminary, unaudited estimates. It extends the reported non-use period; it does not turn June’s capacity figure into a verified October balance.
The narrow wording matters. “No shares sold under this programme” does not mean “no financing of any kind”. A company can have other arrangements, and a single paragraph cannot establish its complete funding history.
Interpretation: Adding the remaining capacity to cash would skip the conditions between permission to sell and cash received. Those include executing sales and paying the associated costs. Capacity may offer flexibility without having funded a single additional operating payment during the period being discussed.
Fact: an old facility can stop being available
Novavax (NASDAQ: NVAX) supplies a different check. Its June 2026 quarterly filing describes an August 2023 agreement that allowed sales of up to $500 million in gross proceeds. The shelf registration statement expired in February 2026, terminating that agreement. Novavax reported no sales under it in the first six months of 2026 before expiry.
Interpretation: Repeating the original $500 million ceiling as currently available funding would erase the termination. The original announcement remains part of the history; the later filing changes what can be inferred from it.
This says nothing, by itself, about whether Novavax needs another equity transaction or what terms it could obtain. Nor does the end of one agreement establish that every possible funding route has closed. The useful finding is specific: this old arrangement cannot simply be carried forward as an unchanged source of capacity.
Fact: completed proceeds have a different description
FuelCell Energy (NASDAQ: FCEL) reported a completed underwritten offering on 9 July 2026 in its July quarterly filing. It issued 12,321,429 common shares at $21 each, including the underwriters’ option, and reported approximately $245.5 million of net proceeds.
That is evidence of capital raised. It is stronger than a headline ceiling because it identifies completion, issued shares and money after transaction costs. It still does not establish how much of that money remained unspent on a later date.
For comparison, the offering prospectus supplement described the securities and transaction terms. The later quarterly filing records the completed outcome. Reading the documents in sequence avoids treating a proposed transaction and its eventual result as interchangeable.
Interpretation: A useful financing account follows three stages: the route available, the sales completed and the subsequent use of cash. Each needs its own date. Combining them into one impressive number makes the story less informative.
Speculation: the same cash target can require different share counts
Consider a fictional company seeking $20 million in gross proceeds. At an assumed sale price of $2 per share, it would issue 10 million shares. At $1, the same gross target would require 20 million shares. These are invented prices, with no forecast attached to any named company.
Suppose 40 million shares were outstanding beforehand and an unchanged holder owned 400,000. That holding initially represents 1%. After 10 million new shares, it represents 0.8% of 50 million. After 20 million new shares, it represents about 0.67% of 60 million.
The illustration assumes identical ordinary shares, no other issuance, no repurchases and a holder who does not participate. It ignores fees. Net proceeds would be lower than gross proceeds if costs were deducted.
It also leaves business value deliberately unresolved. The company receives capital and may put it to productive use, meet obligations or fund continuing losses. A smaller ownership percentage is not a complete valuation model. Put the new shares in the denominator, then examine what the proceeds finance.
Who could benefit?
Interpretation: Plug Power could benefit operationally from usable equity capacity if completed sales provide funds when required on acceptable terms. FuelCell Energy’s completed offering provides a firmer historical starting point: capital had been raised. Over subsequent quarters, any benefit depends on what the businesses achieve with financing and how quickly cash is consumed.
Novavax belongs in the comparison because its filing demonstrates why an expired route must be removed from that assessment. Any future equity-funded benefit would require a separate valid arrangement and completed sales. The old ceiling supplies neither.
These financing mechanisms can matter materially to an issuer’s funding choices. This article does not quantify an earnings benefit or rank funding adequacy. Evidence of expenditure, operating cash generation and obligations would be needed to assess how far proceeds carry each business. More capital raised is not automatically more value created for each existing share.
Who’s at risk?
Interpretation: Existing holders of Plug Power or FuelCell Energy face ownership dilution when additional shares are issued and their holdings stay unchanged. For FuelCell Energy, the cited completed offering is an actual issuance; for Plug’s unused ATM capacity at the stated date, future issuance remains conditional. Novavax’s expired agreement supplies no basis for counting hypothetical new shares as already issued.
The issuer faces a separate constraint. If a future sale price is lower, a fixed gross cash target requires more shares, as the fictional example shows. If sales cannot be completed on acceptable terms, displayed capacity may fail to supply the expected funding. These are business mechanisms, not predictions of share-price falls or findings of present financing failure.
Speculation: Over coming reporting periods, an issuer might use capacity, replace an arrangement or obtain funding elsewhere. No probability is assigned. Dated sale disclosures and subsequent filings would resolve those possibilities; the existence of an agreement alone cannot.
The next useful disclosure
This is a reading framework, not a full audit of three companies’ finances. The selected filings have different period ends, and their figures are not comparable measures of current liquidity. Later transactions can change the position. The historical figures do not establish the terms or availability of financing today.
The evidence that changes the account is concrete: an agreement’s current status, completed sales, gross and net proceeds, updated shares outstanding, and cash used since receipt. A big funding ceiling starts that enquiry. It does not finish it.
Sources checked on 20 October 2026. Informational editorial analysis, not investment advice or a recommendation concerning any security.